Aridis Pharmaceuticals Inc. (ARDS) News

Aridis Pharmaceuticals Inc. (ARDS): $0.06

0.00 (-1.86%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add ARDS to Watchlist
Sign Up

Filter ARDS News Items

ARDS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARDS News Highlights

  • For ARDS, its 30 day story count is now at 3.
  • Over the past 10 days, the trend for ARDS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ARDS are AR, DRUG and RAIL.

Latest ARDS News From Around the Web

Below are the latest news stories about ARIDIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARDS as an investment opportunity.

Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET).

Yahoo | June 30, 2023

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Yahoo | June 21, 2023

Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacteri

Yahoo | June 20, 2023

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023. First Quarter & Subsequent Highlights Met primary safety and secondary pharmacokinetics endpoints in AR-501 Phase 2a study in cystic fibrosis (CF). CF patients achiev

Yahoo | June 8, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning!

William White on InvestorPlace | June 1, 2023

Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

Yahoo | June 1, 2023

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitaliz

Yahoo | May 31, 2023

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 23, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules (the “Listing Rules”) due to the Company’s inability to timely file its Form 10-Q for the three month

Yahoo | May 25, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!

William White on InvestorPlace | April 3, 2023

Aridis Provides Corporate Update

LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments. The Company received written notice from MedImmune Limited (“MedImmune”) terminating a certain license covering AR-320, a product candidate currently being evaluated for the prevention of Ventilator Acquired Pneumonia (VAP) in a Phase 3 clinical trial, between the companies (“License

Yahoo | March 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!